Statin use and the risk of breast cancer

被引:83
作者
Beck, P
Wysowski, DK
Downey, W
Butler-Jones, D
机构
[1] Saskatchewan Hlth, Populat Hlth Branch, Regina, SK S4S 6X6, Canada
[2] US FDA, Div Drug Risk Evaluat, Rockville, MD 20857 USA
关键词
statin drugs; breast cancer; lipid-lowering drugs; hormone replacement therapy; postmenopausal women; Saskatchewan;
D O I
10.1016/S0895-4356(02)00614-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The study objective was to investigate a possible association between statin use and breast cancer (BRCA). An historical cohort design based on Saskatchewan's population health services databases was used. All eligible women with greater than or equal to1 statin prescription from 1989 to mid-1997 and an age-sex-matched nonexposed group were followed up to 8.5 years (mean 4.2 years). Relative rates (RR) of BRCA were estimated and stratified by age, statin exposure time, and prior hormone use. Thirteen thousand five hundred ninety-two statin users and 53,880 nonexposed subjects were identified. Eight hundred seventy-nine incident BRCA cases were identified. Statins were not associated with BRCA risk in women less than or equal to55 years. Among subjects >55 years, the RR for BRCA was 1.15 (0.97, 1.37). Stratified analyses revealed increases in risk in short-term statin users and statin users with long-term hormone replacement therapy (HRT) exposure. More studies are needed to determine if short-term statin use and statin use with long-term HRT exposure increases postmenopausal BRCA risk. Published by Elsevier Science Inc.
引用
收藏
页码:280 / 285
页数:6
相关论文
共 23 条
  • [1] Non-lipid-related effects of statins
    Bellosta, S
    Ferri, N
    Bernini, F
    Paoletti, R
    Corsini, A
    [J]. ANNALS OF MEDICINE, 2000, 32 (03) : 164 - 176
  • [2] Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
  • [3] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA
    BRADFORD, RH
    SHEAR, CL
    CHREMOS, AN
    DUJOVNE, C
    DOWNTON, M
    FRANKLIN, FA
    GOULD, AL
    HESNEY, M
    HIGGINS, J
    HURLEY, DP
    LANGENDORFER, A
    NASH, DT
    POOL, JL
    SCHNAPER, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) : 43 - 49
  • [4] ESTROGEN REPLACEMENT THERAPY AND BREAST-CANCER RISK
    BRINTON, LA
    SCHAIRER, C
    [J]. EPIDEMIOLOGIC REVIEWS, 1993, 15 (01) : 66 - 79
  • [5] Safety profiles for the HMG-CoA reductase inhibitors - Treatment and trust
    Davidson, MH
    [J]. DRUGS, 2001, 61 (02) : 197 - 206
  • [6] Downey W, 2000, PHARMACOEPIDEMIOLOGY, V3rd, P325
  • [7] Statins and blockers of the renin-angiotensin system - Vascular protection beyond their primary mode of action
    Faggiotto, A
    Paoletti, R
    [J]. HYPERTENSION, 1999, 34 (04) : 987 - 996
  • [8] Hormone replacement therapy and risk of breast cancer with a favorable histology - Results of the Iowa Women's Health Study
    Gapstur, SM
    Morrow, M
    Sellers, TA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (22): : 2091 - 2097
  • [9] The cholesterol controversy
    Geurian, KL
    [J]. ANNALS OF PHARMACOTHERAPY, 1996, 30 (05) : 495 - 500
  • [10] Cholesterol lowering with statin drugs, risk of stroke, and total mortality - An overview of randomized trials
    Hebert, PR
    Gaziano, JM
    Chan, KS
    Hennekens, CH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (04): : 313 - 321